Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

BACKGROUND: CIGB-247 is a cancer therapeutic vaccine that uses as antigen a variant of human vascular endothelial growth factor (VEGF) mixed with the bacterially-derived adjuvant VSSP. CIGB-247 has been already evaluated in two phase I clinical trials (CENTAURO and CENTAURO-2), showing to be safe an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez Ramírez, Javier, Morera Díaz, Yanelys, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Martín Bauta, Yenima, Selman-Housein Bernal, Katty-Hind, de la Torre Santos, Ana Victoria, Pérez de la Iglesia, Mariela, Trimiño Lorenzo, Lian, Ayala Avila, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071683/
https://www.ncbi.nlm.nih.gov/pubmed/32171254
http://dx.doi.org/10.1186/s12865-020-0338-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071683/
https://www.ncbi.nlm.nih.gov/pubmed/32171254
http://dx.doi.org/10.1186/s12865-020-0338-4

Ejemplares similares